RedHill Biopharma Ltd. (RDHL)

0.4628 +0.0078 (+1.71%) At close: 04:00PM EDT

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 53

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Dror Ben-Asher	Co-Founder, Chairman & CEO	594.61k	N/A	1966
Mr. Razi Ingber	Chief Financial Officer	339.82k	N/A	1984
Mr. Gilead Raday MPhil, MSc	Chief Operating Officer	365.56k	N/A	1975
Mr. Adi Frish	Chief Corporate & Business Development Officer	339.3k	N/A	1970
Mr. Rick D. Scruggs	Chief Commercial Officer, President of RedHill Biopharma Inc. & Director	469.8k	N/A	1960
Ms. Alexandra Okmian	Senior Business Development & Investor Relations Manager	N/A	N/A	N/A
Dr. Reza Fathi Ph.D.	Senior Vice President of Research & Development	299.29k	N/A	1955
Mr. Guy Goldberg J.D.	Chief Business Officer	338.13k	N/A	1976
Dr. June S. Almenoff FACP, M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1957
Ms. Patricia Anderson B.Sc. RAC	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Corporate governance

RedHill Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.